Compounded Medications Disclosure

Compounded medications are prepared by a licensed pharmacy based on a specific prescription written for an individual patient. Compounding allows for customization of dose, form, or excipients that are not available in commercial products.

Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. They are not generic equivalents of brand-name drugs. The active pharmaceutical ingredients used in our compounded preparations are sourced from FDA-registered facilities, but the finished compounded product is not an FDA-approved product.

Compounded prescriptions are dispensed under Section 503A of the federal Food, Drug, and Cosmetic Act, which permits a licensed pharmacy to compound a medication for an individual patient pursuant to a valid prescription. We work only with state-licensed pharmacies that follow USP standards for sterile and non-sterile compounding.

As of April 2026, the FDA removed several peptides — including BPC-157, TB-500, Sermorelin, Ipamorelin, CJC-1295, and Tesamorelin — from the Category 2 list following withdrawal of their nominations. These peptides are pending Pharmacy Compounding Advisory Committee (PCAC) review scheduled for July 23–24, 2026. We will update our offerings as regulatory guidance evolves.

For GLP-1 therapy, FDA-approved brand-name medications (Wegovy®, Zepbound®, Ozempic®, Mounjaro®) are available. Your clinician will discuss whether a compounded or brand-name pathway is appropriate for you based on clinical indication and other factors. We can route prescriptions for FDA-approved products to your local pharmacy.

You always have the right to ask your clinician about brand-name alternatives, the source of compounded ingredients, and the pharmacy fulfilling your prescription. We encourage you to ask.